Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
about
A syndrome with congenital neutropenia and mutations in G6PC3p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasisTrial watch: Dendritic cell-based anticancer therapyPrimary sterile necrotic cells fail to cross-prime CD8(+) T cellsHAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)In vitro generation of human CD86+ dendritic cells from CD34+ haematopoietic progenitors by PMA and in serum-free mediumEnteropathogenic Escherichia coli and vaccinia virus do not require the family of WASP-interacting proteins for pathogen-induced actin assemblyTranscriptional repressor Gfi1 integrates cytokine-receptor signals controlling B-cell differentiation.WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo.Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo.Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.Cancer gene therapy: developments to 2000.Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation.Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity.Isolation of amniotic stem cell lines with potential for therapy.Spinning molecular immunology into successful immunotherapy.Prospects for immunotherapy of malignant disease.Cytokines and antitumor immunity.Coregulator-dependent facilitation of chromatin occupancy by GATA-1.Dendritic cell activation and maturation induced by recombinant calreticulin fragment 39-272.Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo.Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.Trial watch: Dendritic cell-based interventions for cancer therapyCombinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage.Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015Comparative analysis of cancer vaccine settings for the selection of an effective protocol in miceInterleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependentPeptidases released by necrotic cells control CD8+ T cell cross-priming.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?Blood cells and their use in active immunotherapy of prostate cancer.Immune response to sipuleucel-T in prostate cancerPattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectorsMutations in growth factor independent-1 associated with human neutropenia block murine granulopoiesis through colony stimulating factor-1.
P2860
Q24655459-9CEF23E1-4A0C-4645-BD82-C814DFF79A97Q24682554-A3C5609E-1B30-4571-A3CB-50BBEE807EE2Q27024047-B922B672-3021-42B9-A2EF-65398CDC94CAQ28279623-639B1757-2AA9-469D-A48E-E9F67A49EE6EQ28280427-A239D61D-249C-4C79-84B4-E336ED157498Q28347565-88B6E1E2-E266-4A0F-9F8C-2CDC68BAD03BQ28590623-685A959E-322A-41A6-A0A9-FE69EADC0DECQ33279526-945EB5B4-9D21-4862-BB45-DBD0EE0170EDQ33365455-8CDDBE0D-B1B7-487C-A49A-43603DEFE34EQ33408529-52BE353F-1EB9-4616-B51C-51688906B7BFQ33413888-97411535-7B18-4D6A-8D18-CD2853D86122Q33864097-5BFA7FC3-3589-4369-9A6E-505DFB320EC3Q34068188-ADC4FAFB-C905-4496-805B-69D69E99DA46Q34090963-9D08CB3E-7A04-4F23-B469-E69CD395F574Q34281901-BB6306EF-CA4C-4067-9EAE-4FAD4C4DD7B3Q34441115-1E75D319-AE1A-455D-8A14-FC915A9F1AF5Q34598404-672DD5D1-19AE-4663-A1D1-25E95B7C6E3DQ34632056-7E40C262-398E-45C7-B83B-A31288CE7064Q35041705-1591352F-3C69-43B1-8816-E3220C3B71A5Q35142319-B5F7D6D7-25BE-44DB-BDE6-C6198C5D7BA7Q35730757-0A996261-52DE-49F2-A447-3834B0512D60Q35870735-1647CE15-EFF4-449F-B2EA-4C7AF7748C5AQ36150417-18361192-E213-4AC3-9C15-A67A657F970CQ36236655-EFABF1EC-5D31-4911-9044-3D59FA785A9DQ36369741-52D1C6EB-7B93-40BD-88B8-CA528A2B7D82Q36388529-F8978B29-8912-42C5-B2DE-4F315FBAFA1FQ36422849-2E0BCEF6-82CF-4C62-BA0E-B31D8A0579C9Q36509862-FAD2DAC6-532A-4357-9B33-DF95A80DABB2Q36822947-C6C56E9D-4ECD-4536-89E0-4B840F9E5202Q36859227-A198E2B7-63FF-478A-859C-189939D71477Q36908573-1E859F8F-5D6D-45C9-A98C-0D696DA6FB38Q37259198-90F9A201-92FD-48DB-BC28-2398537F9E50Q37635491-CE419E24-73D9-45C3-852C-EAAC49FCDE6BQ37641531-0BE342F4-2F16-4E6C-82B2-1397A23EFCEAQ37809878-FABD7951-5510-4CAB-A687-B08DBAACBDE4Q37988722-93DAED9C-E087-4F3E-AF00-442EFB723825Q38161390-5F05CA97-EF91-4C2A-A8C6-4897B3A03366Q38450454-B0518524-9818-4CAF-9B8E-C3FEEED1EE04Q38839323-E7EC03F3-84F3-4556-86C4-E9F6EFC6987BQ39519390-BDBDDB63-2A9B-4924-954B-EE95C6AF3E50
P2860
Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@ast
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@en
type
label
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@ast
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@en
prefLabel
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@ast
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@en
P2093
P2860
P356
P1476
Comparative analysis of geneti ...... s therapeutic cancer vaccines.
@en
P2093
P2860
P304
P356
10.1084/JEM.191.10.1699
P407
P577
2000-05-01T00:00:00Z